filmov
tv
Dr Ruben Mesa on Fedratinib’s Impact on Health-Related Quality of Life
Показать описание
Research has shown that fedratinib favorably impacts health-related quality of life for patients with myelofibrosis across the board, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
0:01:42
Dr. Mesa on Ruxolitinib Vs Fedratinib in Myelofibrosis Treatment
0:01:29
Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis
0:15:04
MedNews Week Keynote - New Therapies for Myeloproliferative Neoplasms - Dr. Ruben Mesa
0:18:48
Momelotinib (Ojjaara) for Myelofibrosis: Top 10 Patients & Physicians should know post FDA Appro...
0:28:27
What Should You Expect from Your MPN Treatment? Ruben A. Mesa, MD, FACP
0:01:49
Advances in the science and treatment of MPNs
0:08:56
When Should Clinicians Treat Myelofibrosis With Momelotinib?
0:05:10
Fedratinib in MF: JAKARTA2 and FREEDOM Trials
0:03:28
Should we treat asymptomatic (‘early’) myelofibrosis with JAKi?
0:09:08
What Drives Frontline Treatment Decisions in Patients With Myelofibrosis?
0:02:04
Design and results of PERSIST-1 trial of pacritinib for myelofibrosis
0:22:08
Inadequate or Loss of Response to Ruxolitinib and Combination Strategies in Myelofibrosis
0:19:35
Conference Briefs: Highlighting Myelofibrosis Clinical Data from Key Conferences - Current and em...
1:23:15
Drs.Verstovsek & Mesa discuss latest Myelofibrosis updates from #SOHO2021: https://bit.ly/3hfP1k...
0:37:14
Risk-Adapted Treatment in Myelofibrosis: JAK Inhibitors and Novel Combination Therapies
0:58:48
How to Manage JAK Inhibition in Patients Undergoing HCT
0:19:54
Therapy for “Early Myelofibrosis”: Pros and Cons
1:20:00
Understanding Myelofibrosis: Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
0:01:32
Dr David Snyder Outlines Use of Ruxolitinib After Approval of Fedratinib
0:01:23
RESPONSE-2 5-year follow-up update: ruxolitinib vs BAT in polycythemia vera without splenomegaly
0:03:55
Response to Ruxolitinib Therapy for Polycythemia Vera
0:16:29
Inadequate or Loss of Response to Ruxolitinib, and Combination Strategies
0:01:52
MPN updates: trial updates, combinations & novel therapies
0:25:15
How to Manage Side Effects of JAK Inhibitors for Mylofibrosis in the Clinical Practice
Комментарии